Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges

Asian Journal of Pharmaceutical Sciences

Volumn 10, Issue 6, 2015, Pages 481-489

  Lee, Wing Hin ^a   Loo, Ching Yee ^a   Traini, Daniela ^a   Young, Paul M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Inhalation; Liposome; Lung cancer; Nanoparticle

Indexed keywords

ANTINEOPLASTIC AGENT; GELATIN; LIPOSOME; NANOPARTICLE;

AEROSOL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; HUMAN; LIPOSOMAL DELIVERY; LUNG CANCER; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICOCHEMICAL MODEL; REVIEW; SURFACE PROPERTY;

EID: 84959541739     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2015.08.009     Document Type: Review

References (73)

1. Cancer Research UK crukorg/cancerstats 2013.
2. Jemal A., Bray F., Center M.M., et al. Global cancer statistics 2011, vol. 61:69-90. A Cancer Journal for Clinicians, CA.
3. Centers for Disease Control and Prevention (US) The Health Consequences of Smoking: A Report of the Surgeon General 2004, Office of the Surgeon General (US); Office on Smoking and Health (US); Atlanta, GA.
4. Rodriguez E., Lilenbaum R. Small cell lung cancer: past, present, and future. Curr Oncol Rep 2010, 12:327-334.
5. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
6. Paumier A., Le Péchoux C. Radiotherapy in small-cell lung cancer: where should it go?. Lung Cancer 2010, 69:133-140.
7. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. NEJM 2004, 350:351-360.
8. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000, 18:122.
9. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NEJM 2002, 346:92-98.
10. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998, 16:2459-2465.
11. Karathanasis E., Ayyagari A.L., Bhavane R., et al. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J Control Release 2005, 103:159-175.
12. Loira-Pastoriza C., Todoroff J., Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014, 75:81-91.
13. Ruge C.A., Kirch J., Lehr C.M. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers - therapeutic possibilities and technological challenges. Lancet Respir Med 2013, 1:402-413.
14. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007, 25:563-570.
15. Fels A.O.S., Cohn Z.A. The alveolar macrophage. J Appl Physiol 1986, 60:353-369.
16. Dhanikula A.B., Panchagnula R. Localized paclitaxel delivery. Int J Pharm 1999, 183:85-100.
17. Carstens M.G., de Jong P.H.J.L.F., van Nostrum C.F., et al. The effect of core composition in biodegradable oligomeric micelles as taxane formulations. Eur J Pharm Biopharm 2008, 68:596-606.
18. Solubility A.A. Absorption and drug development 2003, 91-115. John Wiley & Sons, Inc.
19. Hansch C., Leo A., Hoekman D. Exploring QSAR: hydrophobic, electronic, and steric constants American Chemical Society 1995.
20. Stella B., Arpicco S., Rocco F., et al. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharmaceut 2007, 344:71-77.
21. Cantrell C.L., Franzblau S.G., Fischer N.H. Antimycobacterial plant terpenoids. Planta Med 2001, 67:685-694.
22. Seedher N., Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. Aaps Pharmscitech 2003, 4:36-44.
23. Hamman J.H., Enslin G.M., Kotze A.F. Oral delivery of peptide drugs: barriers and developments. Biodrugs 2005, 19:165-177.
24. Todoroff J., Vanbever R. Fate of nanomedicines in the lungs. Curr Opin Colloid Interface Sci 2011, 16:246-254.
25. Rubin B.K. Mucus, phlegm, and sputum in cystic fibrosis. Respir Care 2009, 54:726-732.
26. Ensign L.M., Schneider C., Suk J.S., et al. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater 2012, 24:3887-3894.
27. Hunt B.E., Weber A., Berger A., et al. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995, 39:34-39.
28. Cone R.A. Barrier properties of mucus. Adv Drug Deliv Rev 2009, 61:75-85.
29. Sigurdsson H.H., Kirch J., Lehr C.-M. Mucus as a barrier to lipophilic drugs. Int J Pharm 2013, 453:56-64.
30. d'Angelo I., Conte C., La Rotonda M.I., et al. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev 2014, 75:92-111.
31. Patton J.S., Fishburn C.S., Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1:338-344.
32. Schanker L.S., Less M.J. Lung pH and pulmonary absorption of nonvolatile drugs in the rat. Drug Metabol Dispos 1977, 5:174-178.
33. Lü J.-M., Wang X., Marin-Muller C., et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009, 9:325-341.
34. Gabizon A.A., Shmeeda H., Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006, 16:175-183.
35. Mukherjee S., Ray S., Thakur R.S. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009, 71:349-358.
36. Dolovich M.B., Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377:1032-1045.
37. Respaud R., Vecellio L., Diot P., et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv 2015, 12:1027-1039.
38. Anderson P. Use of respimat(®) soft Mist™ inhaler in COPD patients. Int J Chronic Obstruct Pulmon Dis 2006, 1:251-259.
39. Lee W.-H., Loo C.-Y., Young P.M., et al. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv 2014, 11:1183-1201.
40. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
41. Tomoda K., Ohkoshi T., Hirota K., et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces 2009, 71:177-182.
42. Azarmi S., Tao X., Chen H., et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006, 319:155-161.
43. Kim I., Byeon H.J., Kim T.H., et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012, 33:5574-5583.
44. Kim I., Byeon H.J., Kim T.H., et al. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials 2013, 34:6444-6453.
45. Feng T., Tian H., Xu C., et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm 2014, 88:1086-1093.
46. Lee W.-H., Loo C.-Y., Traini D., et al. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv 2015, 12:1009-1026.
47. Koshkina N.V., Waldrep J.C., Roberts L.E., et al. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001, 7:3258-3262.
48. Song H., Zhang J., Liu X., et al. Development of a bone targeted thermosensitive liposomal doxorubicin formulation based on a bisphosphonate modified non-ionic surfactant. Pharm Dev Technol 2015;15:1-8.
49. Jinturkar K.A., Anish C., Kumar M.K., et al. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 2012, 33:2492-2507.
50. Koshkina N.V., Golunski E., Roberts L.E., et al. Cyclosporin a aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004, 17:7-14.
51. Koshkina N.V., Kleinerman E.S., Waldrep C., et al. 9-nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 2000, 6:2876-2880.
52. Knight V., Kleinerman E.S., Waldrep J.C., et al. 9-nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 2000, 922:151-163.
53. Verschraegen C.F., Gilbert B.E., Loyer E., et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004, 10:2319-2326.
54. Perkins W., Weers J., Meers P., et al. An inhalation formulation of liposomal cisplatin (SLIT2 cisplatin) for treatment of lung cancer 2005, Lipids, Liposomes & Biomembranes, Vancouver.
55. Wittgen B.P.H., Kunst P.W.A., van der Born K., et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007, 13:2414-2421.
56. Skubitz K.M., Anderson P.M. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000, 11:555-563.
57. Kommareddy S., Shenoy D.B., Amiji M.M. Gelatin nanoparticles and their biofunctionalization. Nanotechnologies for the life sciences 2005, 330-352. WILEY-VCH Verla GmbH & Co. KGaA, Weinheim. C.S.S.R. Kumar (Ed.).
58. Elzoghby A.O. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release 2013, 172:1075-1091.
59. Lu Z., Yeh T.-K., Wang J., et al. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol 2011, 185:1478-1483.
60. Tseng C.-L., Su W.-Y., Yen K.-C., et al. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
61. Cao F., Ding B., Sun M., et al. Lung-targeted delivery system of curcumin loaded gelatin microspheres. Drug Deliv 2011, 18:545-554.
62. Karthikeyan S., Rajendra Prasad N., Ganamani A., et al. Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomed Prev Nutr 2013, 3:64-73.
63. Cascone M., Lazzeri L., Carmignani C., et al. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med 2002, 13:523-526.
64. Tseng C.-L., Wang T.-W., Dong G.-C., et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007, 28:3996-4005.
65. Tseng C.-L., Wu S.Y.-H., Wang W.-H., et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29:3014-3022.
66. Roa W.H., Azarmi S., Al-Hallak M.H.D.K., et al. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011, 150:49-55.
67. Al-Hallak M.H.D.K., Sarfraz M.K., Azarmi S., et al. Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an in vivo study. Ther Deliv 2012, 3:725-734.
68. Kaminskas L.M., McLeod V.M., Ryan G.M., et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release 2014, 183:18-26.
69. Choi S.H., Byeon H.J., Choi J.S., et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 2015, 197:199-207.
70. Taratula O., Garbuzenko O.B., Chen A.M., et al. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011, 19:900-914.
71. Taratula O., Kuzmov A., Shah M., et al. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013, 171:349-357.
72. Patlolla R.R., Chougule M., Patel A.R., et al. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010, 144:233-241.
73. Hitzman C.J., Wattenberg L.W., Wiedmann T.S. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 2006, 95:1196-1211.